Little, Annette S <br/><br/>
A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.  [electronic resource] 

 -  Science signaling  2011 
 - er2 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Corrected and Republished Article 
<br/><br/><label>ISSN: </label>1937-9145 
<br/><br/><label>Standard No.: </label>10.1126/scisignal.4170er2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzimidazoles<br/>Cell Cycle--drug effects<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Colorectal Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm--genetics<br/>Gene Amplification<br/>Genes, ras<br/>Humans<br/>MAP Kinase Signaling System--drug effects<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Up-Regulation<br/>ras Proteins--genetics